Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349830 · ClinicalTrials.gov registry record
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
A clinical trial of Neoplasms and Carcinomas (Including Squamous Cell and Adenocarcinoma), sponsored by Stanford University.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT00349830: Recruiting study of Neoplasms and Carcinomas (Including Squamous Cell and Adenocarcinoma), sponsored by Stanford University.
NCT00349830 is a study of Neoplasms and Carcinomas (Including Squamous Cell and Adenocarcinoma) that is actively recruiting participants, run by Stanford University. The registered enrollment target is 2,000 participants, above the 1,609-participant average among 158 other Neoplasms trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349830, a study of Neoplasms and Carcinomas (Including Squamous Cell and Adenocarcinoma), is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Conditions Studied
Interventions
- PROCEDURE blood draw
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2002-01 |
| Est. Completion | 2032-01 |
What NCT00349830 shows while recruiting
NCT00349830 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,609-participant average among 158 other Neoplasms trials with a reported enrollment target (24% higher).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which blood draw is the first listed.
NCT00349830 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00349830 about?
NCT00349830 is a clinical study titled "Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy". The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. ...
What is the current status of trial NCT00349830?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2002-01. Estimated completion is 2032-01.
What conditions does trial NCT00349830 study?
This clinical trial studies the following conditions: Neoplasms, Carcinomas (Including Squamous Cell and Adenocarcinoma).
What interventions are being tested in trial NCT00349830?
The interventions under investigation include: blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT00349830?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00349830 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00349830's enrollment target sits among peer trials
2,000 10th of 158 higher than 149 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Resilience in East Asian Immigrants for Advance Care Planning Discussions
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia